Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 757 of 5804
-
Could this pill help kids with rare lung disease?
Disease control OngoingThe purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for chronic itch: dupilumab tackles prurigo nodularis
Disease control CompletedPrimary Objective: To demonstrate the efficacy of dupilumab on itch response in participants with prurigo nodularis (PN), inadequately controlled on topical prescription therapy or when those therapies are not advisable. Secondary Objectives: To demonstrate the efficacy of dup…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 17:54 UTC
-
New hope for kids with NF1 brain tumors: targeted drug may beat chemo
Disease control OngoingThis phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pa…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for tough lymphoma: experimental drug CHO-H01 enters human trials
Disease control Recruiting nowThis is a 2-part study. Part 1/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma. It will also determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D). …
Phase: PHASE1, PHASE2 • Sponsor: Cho Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Heart-Saving combo: steroid plus standard therapy may shield kids from kawasaki damage
Disease control CompletedThis study evaluates the efficacy of the addition of prednisolone to conventional initial treatment (intravenous immunoglobulin \[IVIG\] plus aspirin) in reducing coronary artery lesion in children with Kawasaki disease (KD) .
Phase: PHASE3 • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug cocktail shows promise for rare sarcomas
Disease control OngoingThis phase II trial studies how well cabozantinib and temozolomide work in treating patients with leiomyosarcoma or other soft tissue sarcoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Cabozantinib may stop the growth …
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
HIV vaccine candidate moves to human safety tests
⭐️ VACCINE ⭐️ CompletedThe purpose of this study is to evaluate the safety and immunogenicity of HIV-1 BG505 SOSIP.664 gp140 with TLR agonist and/or alum adjuvants in healthy, HIV-uninfected adults.
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 13:17 UTC
-
New combo therapy shows promise for Tough-to-Treat cervical cancer
Disease control CompletedThis is an open-label, single-arm, phase II, multi-center clinical trial. Subjects can only enter this study after they meet the inclusion and exclusion criteria. All enrolled patients will receive the treatment with anti-PD-1 combined with albumin-bound paclitaxel, every 3 weeks…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take aim at tough childhood cancers
Disease control CompletedThe primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from pediatric and young adult subjects with relapsed/refractory B-cell malignancies (leukemia and lymphoma). Another purpose of this study is to test the sa…
Phase: PHASE1 • Sponsor: Kara Lynn Davis • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New weekly shot could help control bleeding in hemophilia a
Disease control CompletedThis study is investigating how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medication that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII …
Phase: PHASE2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New cocktail aims to deeply suppress bone marrow cancer
Disease control OngoingThis study is being done because, despite major advances in therapy, MM is still considered an incurable disease. The purpose of this study is to determine the efficacy (how well it works) of the study treatment that combines the following drugs: daratumumab, carfilzomib, lenalid…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Gene-Fixed skin patches tested for rare 'Butterfly' disease
Disease control OngoingThis phase I/II clinical trial aims to treat 3 adult subjects with Recessive Dystrophic Epidermolysis Bullosa, expressing residual C7 levels, by genetically corrected autologous skin equivalent grafts on selected areas (up to 300 cm2).
Phase: PHASE1, PHASE2 • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New heart pill aims to ease thick heart muscle symptoms
Disease control CompletedThis study is being performed to understand the effect of different doses of CK-3773274 on patients with hypertrophic cardiomyopathy (HCM).
Phase: PHASE2 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Tiny lung sensor could keep heart failure patients out of the hospital
Disease control OngoingThis is a prospective, open- label, single arm, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System in NYHA Class III Heart Failure Patients compared to a Performance Goal (PG).
Phase: NA • Sponsor: Endotronix, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Blood filter aims to pull toxins from septic shock patients
Disease control OngoingProspective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
Phase: NA • Sponsor: Spectral Diagnostics (US) Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New pill shows promise for leukemia patients who've run out of options
Disease control Recruiting nowA multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (BP) or with Ph+ ALL, who have e…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Could your own fat cells heal Crohn's fistulas? new trial tests it
Disease control OngoingThis is a phase III study to evaluate the efficacy and safety of ASC(Autologous Adipose-derived Stem Cells) and Fibringlue or Fibringlue in Patients With Crohn's Fistula.
Phase: PHASE3 • Sponsor: Anterogen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New mRNA vaccine shows promise against common virus that can harm newborns
⭐️ VACCINE ⭐️ CompletedThis clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
Hope for rare liver disease: drug aims to ease severe itching in children
Disease control CompletedThe primary objective of this open label extension study is to evaluate the long-term safety and tolerability of maralixibat.
Phase: PHASE3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kidney cancer patients after immunotherapy fails
Disease control CompletedThe overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipil…
Phase: PHASE2 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC